FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1825249855> ?p ?o ?g. }

• W1825249855 endingPage "952" @default.
• W1825249855 startingPage "952" @default.
• W1825249855 abstract "Topical fluorouracil was demonstrated to be effective in reducing the number of actinic keratoses (AKs) for up to 6 months, but no randomized trials studied its long-term efficacy.To evaluate the long-term efficacy of a single course of fluorouracil cream, 5%, for AK treatment.The Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) trial was a randomized, double-blinded, placebo-controlled trial with patients from dermatology clinics at 12 VA medical centers recruited from 2009 to 2011 and followed up until 2013. Our study population comprised 932 veterans with 2 or more keratinocyte carcinomas in the 5 years prior to enrollment. The mean follow-up duration was 2.6 years in both treatment and control groups.Participants applied either topical fluorouracil cream, 5% (n = 468), or vehicle control cream (n = 464) to the face and ears twice daily for up to 4 weeks.This study reports on AK counts and treatments, which were secondary outcomes of the VAKCC trial. Actinic keratoses on the face and ears were counted by study dermatologists at enrollment and at study visits every 6 months. The number of spot treatments for AKs on the face and ears at semiannual study visits and in between study visits was recorded.The number of AKs on the face and ears per participant was not different between the fluorouracil and control groups at randomization (11.1 vs 10.6, P > .10). After randomization, the fluorouracil group had fewer AKs compared with the control group at 6 months (3.0 vs 8.1, P < .001) and for the overall study duration (P < .001). The fluorouracil group also had higher complete AK clearance rates (38% vs 17% at 6 months) and fewer spot treatments at 6-month intervals, at study visits, and in between study visits during the trial (P < .01 for all). The fluorouracil group took longer to require the first spot AK treatment (6.2 months) compared with the control group (6.0 months) (hazard ratio, 0.69; 95% CI, 0.60-0.79). The number of hypertrophic AKs was not different between the 2 groups overall (P = .60), although there were fewer hypertrophic AKs in the fluorouracil group at 6 months (0.23 vs 0.41) (P = .05).Our results indicate that a single course of fluorouracil cream, 5%, effectively reduces AK counts and the need for spot treatments for longer than 2 years.clinicaltrials.gov Identifier:NCT00847912." @default.
• W1825249855 created "2016-06-24" @default.
• W1825249855 creator A5005003304 @default.
• W1825249855 creator A5005468145 @default.
• W1825249855 creator A5006036761 @default.
• W1825249855 creator A5006480686 @default.
• W1825249855 creator A5024432811 @default.
• W1825249855 creator A5027734818 @default.
• W1825249855 creator A5029793095 @default.
• W1825249855 creator A5030849116 @default.
• W1825249855 creator A5043386635 @default.
• W1825249855 creator A5052928814 @default.
• W1825249855 creator A5054744755 @default.
• W1825249855 creator A5062808281 @default.
• W1825249855 creator A5074834465 @default.
• W1825249855 creator A5090541376 @default.
• W1825249855 creator A5090712336 @default.
• W1825249855 date "2015-09-01" @default.
• W1825249855 modified "2023-10-15" @default.
• W1825249855 title "Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis" @default.
• W1825249855 cites W1512398135 @default.
• W1825249855 cites W1526173865 @default.
• W1825249855 cites W1647316669 @default.
• W1825249855 cites W1832821854 @default.
• W1825249855 cites W1933295591 @default.
• W1825249855 cites W1973780986 @default.
• W1825249855 cites W1974724292 @default.
• W1825249855 cites W1980038941 @default.
• W1825249855 cites W2010053788 @default.
• W1825249855 cites W201253639 @default.
• W1825249855 cites W2025025945 @default.
• W1825249855 cites W2025039194 @default.
• W1825249855 cites W2025556270 @default.
• W1825249855 cites W2027596799 @default.
• W1825249855 cites W2039477787 @default.
• W1825249855 cites W2044030923 @default.
• W1825249855 cites W2045888731 @default.
• W1825249855 cites W2061766707 @default.
• W1825249855 cites W2080801407 @default.
• W1825249855 cites W2081565097 @default.
• W1825249855 cites W2089184013 @default.
• W1825249855 cites W2110846194 @default.
• W1825249855 cites W2112391921 @default.
• W1825249855 cites W2114503152 @default.
• W1825249855 cites W2116254531 @default.
• W1825249855 cites W2120878621 @default.
• W1825249855 cites W2135825792 @default.
• W1825249855 cites W2138530019 @default.
• W1825249855 cites W2150346360 @default.
• W1825249855 cites W2157052759 @default.
• W1825249855 cites W2183367034 @default.
• W1825249855 cites W2256523494 @default.
• W1825249855 cites W2398668449 @default.
• W1825249855 cites W2407189421 @default.
• W1825249855 cites W73602638 @default.
• W1825249855 doi "https://doi.org/10.1001/jamadermatol.2015.0502" @default.
• W1825249855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25950503" @default.
• W1825249855 hasPublicationYear "2015" @default.
• W1825249855 type Work @default.
• W1825249855 sameAs 1825249855 @default.
• W1825249855 citedByCount "83" @default.
• W1825249855 countsByYear W18252498552015 @default.
• W1825249855 countsByYear W18252498552016 @default.
• W1825249855 countsByYear W18252498552017 @default.
• W1825249855 countsByYear W18252498552018 @default.
• W1825249855 countsByYear W18252498552019 @default.
• W1825249855 countsByYear W18252498552020 @default.
• W1825249855 countsByYear W18252498552021 @default.
• W1825249855 countsByYear W18252498552022 @default.
• W1825249855 countsByYear W18252498552023 @default.
• W1825249855 crossrefType "journal-article" @default.
• W1825249855 hasAuthorship W1825249855A5005003304 @default.
• W1825249855 hasAuthorship W1825249855A5005468145 @default.
• W1825249855 hasAuthorship W1825249855A5006036761 @default.
• W1825249855 hasAuthorship W1825249855A5006480686 @default.
• W1825249855 hasAuthorship W1825249855A5024432811 @default.
• W1825249855 hasAuthorship W1825249855A5027734818 @default.
• W1825249855 hasAuthorship W1825249855A5029793095 @default.
• W1825249855 hasAuthorship W1825249855A5030849116 @default.
• W1825249855 hasAuthorship W1825249855A5043386635 @default.
• W1825249855 hasAuthorship W1825249855A5052928814 @default.
• W1825249855 hasAuthorship W1825249855A5054744755 @default.
• W1825249855 hasAuthorship W1825249855A5062808281 @default.
• W1825249855 hasAuthorship W1825249855A5074834465 @default.
• W1825249855 hasAuthorship W1825249855A5090541376 @default.
• W1825249855 hasAuthorship W1825249855A5090712336 @default.
• W1825249855 hasBestOaLocation W18252498551 @default.
• W1825249855 hasConcept C126322002 @default.
• W1825249855 hasConcept C141071460 @default.
• W1825249855 hasConcept C142724271 @default.
• W1825249855 hasConcept C16005928 @default.
• W1825249855 hasConcept C168563851 @default.
• W1825249855 hasConcept C204243189 @default.
• W1825249855 hasConcept C204787440 @default.
• W1825249855 hasConcept C27081682 @default.
• W1825249855 hasConcept C2775969662 @default.
• W1825249855 hasConcept C2776694085 @default.
• W1825249855 hasConcept C2777873816 @default.

• next